Mitochondrial complex I defect induces ROS release and degeneration in trabecular meshwork cells of POAG patients: protection by antioxidants

Invest Ophthalmol Vis Sci. 2008 Apr;49(4):1447-58. doi: 10.1167/iovs.07-1361.

Abstract

Purpose: There is growing evidence that oxidative stress contributes to the progression of primary open-angle glaucoma (POAG), a leading cause of irreversible blindness worldwide. The authors provide evidence that mitochondrial dysfunction is a possible mechanism for the loss of trabecular meshwork (TM) cells in persons with POAG.

Methods: TM from patients with POAG (GTM) and age-matched subjects without disease (NTM) were obtained by standard surgical trabeculectomy. Primary TM cultures were treated with one of the following mitochondrial respiratory chain inhibitors: rotenone (ROT, complex I inhibitor), thenoyltrifluoroacetone (TTFA, complex II inhibitor), myxothiazol or antimycin A (MYX, AM-complex III inhibitors); mitochondrial permeability transition (MPT) inhibitor cyclosporine A (CsA); and antioxidants vitamin E (Vit E) or N-acetylcysteine (NAC). Mitochondrial function was determined by changes in mitochondrial membrane potential (DeltaPsim) and adenosine triphosphate (ATP) production with the fluorescent probes 5,5',6,6'-tetrachloro-1,1'3,3'-tetraethylbenzimid azolocarbocyanine iodide (JC-1) and a luciferin/luciferase-based ATP assay, respectively. Reactive oxygen species (ROS) level, determined by H(2)-DCF-DA, and cell death, measured by lactate dehydrogenase activity and Annexin V-FITC labeling, were also examined.

Results: GTM cells have higher endogenous ROS levels, lower ATP levels, and decreased Delta Psi m and they are more sensitive to mitochondrial complex I inhibition than their normal counterparts. ROT induces a further increase in ROS production, the release of cytochrome c, and decreases in ATP level and Delta Psi m in GTM cells, eventually leading to apoptosis. Complex II and III inhibition had little effect on the cells. Antioxidants protect against ROT-induced death by inhibiting ROS generation and cytochrome c release.

Conclusions: The authors propose that a mitochondrial complex I defect is associated with the degeneration of TM cells in patients with POAG, and antioxidants and MPT inhibitors can reduce the progression of this condition.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetylcysteine / therapeutic use
  • Adenosine Triphosphate / metabolism
  • Adolescent
  • Adult
  • Annexin A5 / metabolism
  • Antioxidants / therapeutic use*
  • Apoptosis / drug effects*
  • Cells, Cultured
  • Cyclosporine / therapeutic use
  • Cytochromes c / metabolism
  • Electron Transport Complex I / antagonists & inhibitors*
  • Glaucoma, Open-Angle / metabolism
  • Glaucoma, Open-Angle / pathology
  • Glaucoma, Open-Angle / prevention & control*
  • Humans
  • L-Lactate Dehydrogenase / metabolism
  • Membrane Potential, Mitochondrial
  • Middle Aged
  • Mitochondrial Membrane Transport Proteins / antagonists & inhibitors
  • Mitochondrial Permeability Transition Pore
  • Oxidative Stress
  • Reactive Oxygen Species / metabolism*
  • Rotenone / pharmacology
  • Trabecular Meshwork / drug effects*
  • Trabecular Meshwork / metabolism
  • Trabecular Meshwork / pathology
  • Uncoupling Agents / pharmacology*
  • Vitamin E / therapeutic use

Substances

  • Annexin A5
  • Antioxidants
  • Mitochondrial Membrane Transport Proteins
  • Mitochondrial Permeability Transition Pore
  • Reactive Oxygen Species
  • Uncoupling Agents
  • Rotenone
  • Vitamin E
  • Cyclosporine
  • Adenosine Triphosphate
  • Cytochromes c
  • L-Lactate Dehydrogenase
  • Electron Transport Complex I
  • Acetylcysteine